Dr. David Kaminetzky, MD

Dr. Kaminetzky practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Kaminetzky's NPI, 1083702245, was assigned on October 11, 2006. Dr. Kaminetzky graduated from Albert Einstein College of Medicine in 2003. Dr. Kaminetzky holds New York license 235583.

Dr. Kaminetzky's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Kaminetzky's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Kaminetzky is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Kaminetzky to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kaminetzky practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kaminetzky's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kaminetzky is board certified in hematology by the American Board of Internal Medicine. Dr. Kaminetzky is licensed in New York.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, fluid and electrolyte imbalances, lymphoma, multiple myeloma, neutropenia and prostate cancer among the conditions Dr. Kaminetzky treats.

CMS data shows 1,547 Medicare services from Dr. Kaminetzky across 12 procedure codes in 2024, for 538 Medicare patients. Medicare paid $88,067 for them.

CMS counts 538 Medicare patients who saw Dr. Kaminetzky in 2024. The largest group is 75 to 84, with 233 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kaminetzky's median patient age at 71, with 49% women.

In 2024, Dr. Kaminetzky wrote 73 Medicare Part D claims for 27 patients. 82% of them were for generic drugs. CMS names the drug for 21 of them, across 1 drug with 11 or more claims each, at $154 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Kaminetzky for performance year 2024, reported as part of a group. Dr. Kaminetzky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kaminetzky as offering telehealth.

Dmand AI links 12 papers to Dr. Kaminetzky, published from 2017 to 2025. 2020 was the busiest year, with 2. The most frequent topics are Multiple Myeloma. Dr. Kaminetzky's most frequent co-authors are Faith E. Davies, MD, Gareth J. Morgan, MD and Marc Justin Braunstein, MD, PhD.

CMS Open Payments shows 1 general payment to Dr. Kaminetzky from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $31.

Dmand AI lists 1 award for Dr. Kaminetzky, most recently CMS Stage 1 EHR in 2013.

Dr. Kaminetzky graduated from Albert Einstein College of Medicine in 2003.

Dr. Kaminetzky is in network with 18 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.